Redefining bone drug delivery systems.
Redefining bone drug delivery systems.
Osteoporosis affects 200 million people worldwide and occurs when the body removes more bone than it regenerates, weakening bone structure and increasing the risk of fractures. Patients are often treated with bisphosphonates, which inhibit the action of osteoclasts responsible for bone resorption. However, poor blood flow to bone tissue makes it difficult for the medication to effectively reach its target, requiring higher doses and increasing the risk of serious side effects in other parts of the body.
At APASOMICS, we develop advanced biomedical solutions, combining nanotechnology and biotechnology to revolutionize drug delivery and the treatment of bone diseases such as osteoporosis.
* 1 in 3 women and 1 in 5 men over 50 will experience an osteoporosis fracture.
To develop innovative drug delivery systems targeting bones, inspired by natural bone remineralization, improving the effectiveness of treatments like bisphosphonates and reducing their side effects, ultimately contributing to a better quality of life for people with bone diseases.
To become a global leader in drug delivery technology for the treatment of bone diseases, setting new standards in regenerative medicine and licensing Apasomes for various bone-related conditions, promoting a biomimetic approach to bone health.
To develop innovative drug delivery systems targeting bones, inspired by natural bone remineralization, improving the effectiveness of treatments like bisphosphonates and reducing their side effects, ultimately contributing to a better quality of life for people with bone diseases. Our technology dates back 20 years, beginning with the research in nanotechnology conducted by PhD. Mavis Montero Villalobos, focusing on the development of nanoparticles and nanostructures based on hydroxyapatite.
In 2022, the first hydroxyapatite nanosphere was assembled, which we named Apasome. Given the potential applications in the biomedical and biotechnological fields, PhD. Mavis' research team came up with the idea to use this discovery to effectively deliver drugs to bone. As a result, Apasomics was founded in 2024, a startup focused on utilizing this technology for the development of drug delivery systems.
At APASOMICS, we have developed Apasomes, an innovative drug delivery system consisting of hydroxyapatite nanospheres designed to transport drugs like bisphosphonates directly to the bone, improving treatment efficacy and reducing side effects.
How do Apasomes work? Apasomes replicate the natural mechanism of bone cells called osteoblasts, which generate exosomes loaded with hydroxyapatite to restore bone tissue. Mimicking this process, our nanospheres can target the bone and release medication in a controlled and sustained manner.
With this biomimetic technology, APASOMICS offers an advanced treatment alternative that could transform the future of bone health and improve the quality of life for millions worldwide.
NO IMMUNOGENICITY
BIOCOMPATIBILITY
STABILITY
CONTROLLED AND SUSTAINED RELEASE
DUAL TECHNOLOGY
Apasomes Advantages
CEO & Co-Founder
Nanotechnology & Drug Delivery Research.
CSO & Co-Founder
Cell Culture & Preclinical Biotech Development.
COO & Co-Founder
Biotech Project Management & Business Strategy.
Founder and CEO at Speratum Biopharma
IP and Biotech Business Development.
Director CICIMA-UCR
Material Chemistry Innovation Leadership.
CSO at Speratum Biopharma
Biotech Drug Development Strategy.
